2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: Safety and Efficacy of Ac225-PSMA617 in mCRPC after the Failure of Lu177-PSMA

Ottawa, ON, Canada (UroToday.com) Dr. Benedikt Feurecker described a regimen for Ac225 treatment of metastatic castration-resistant prostate cancer (mCRPC) patients.  The idea was to control harmful side effects by adjusting the dose based on careful monitoring of each patient in the periods between Ac225 applications. The initial Ac225 dose was 8 mBq. In week 2-4 after injection, the patient received aftercare checkup, blood tests and documentation of adverse events. In week 6, a PSMA PET scan was used to evaluate patient progress (as well as blood tests and AE documentation). In week 7, an interdisciplinary team evaluated the results and recommended a dose for the next cycle. In week 8, the next cycle was executed.

Of the eighteen patients in the study, most showed some anti-tumor effect but one third had to stop therapy due to xerostomia. In this patient cohort, monitoring to adjust dose had a disappointing ability to control side effects.

Presented by: Dr. Benedikt Feuerecker, Technische Universitat Munchen, Department of Nuclear Medicine.

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada